An update on laboratory measurements of Dabigatran: Smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma

摘要: Use of Direct Oral Anticoagulants (DOACs) is continuously increasing for clinical application. The first product released was Dabigatran, which proposed many preventive and curative applications, especially prevention stroke in patients with non-valvular atrial fibrillation. Although measurement Dabigatran Anti-IIa activity plasma not requested on a routine basis, some situations its clinically useful. Especially, before an emergency surgery treated patients, where presence at high concentrations, will expose the patient increased bleeding risk, has to be excluded. Hence, smart, specific, rapid accurate quantitative assays are warranted as essential required. Hemoclot™ Thrombin Inhibitors Biophen® DTI were specifically designed these can used all automated instruments standard range protocol measuring concentrations peak, or low testing residual concentrations. Both functional have good correlation reference LC-MS/MS method, measured similar. Performances interferences various substances drugs discussed. Some differences variations clotting times observed between mechanical optical clot detection instruments, could explained by fibrin structure, altered direct Factor Xa inhibitors, more Rivaroxaban. chromogenic offer safe this determination requested. In short manuscript provides depth update current opinions laboratory aspects plasma, when